Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-09-04
2004-09-28
Chang, Celia (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C546S236000, C546S237000, C546S241000
Reexamination Certificate
active
06797826
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to piperidine derivatives and a process for their production.
BACKGROUND OF THE INVENTION
Terfenadine, 1-(p-tert-butylphenyl)-4-[4′-(&agr;-hydroxydiphenylmethyl)-1′-piperidinyl]-butanol is a non-sedating anti-histamine. It is reported to be a specific H
2
-receptor antagonist that is also devoid of any anticholingeric, anti-serotoninergic, and anti-adrenergic effects both in vitro and in vivo. See D. McTavish, K. L. Goa, M. Ferrill,
Drugs,
1990, 39, 552; C. R. Kingsolving, N. L. Monroe, A. A. Carr,
Pharmacologist,
1973, 15, 221; J. K. Woodward, N. L. Munro,
Arzneim
-
Forsch,
1982, 32, 1154; K. V. Mann, K. J. Tietze,
Clin. Pharm.
1989, 6, 331. A great deal of effort has been made investigating structure-activity relationships of terfenadine analogs, and this is reflected in the large number of U.S. patents disclosing this compound and related structures as follows:
U.S. Pat. No. 3,687,956 to Zivkovic
U.S. Pat. No. 3,806,526 to Carr, et. al.
U.S. Pat. No. 3,829,433 to Carr, et. al.
U.S. Pat. No. 3,862,173 to Carr, et. al.
U.S. Pat. No. 3,878,217 to Carr, et. al.
U.S. Pat. No. 3,922,276 to Duncan, et. al.
U.S. Pat. No. 3,931,197 to Carr, et. al.
U.S. Pat. No. 3,941,795 to Carr, et. al.
U.S. Pat. No. 3,946,022 to Carr, et. al.
U.S. Pat. No. 3,956,296 to Duncan, et. al.
U.S. Pat. No. 3,965,257 to Carr, et. al.
U.S. Pat. No. 4,742,175 to Fawcett, et. al.
Terfenadine has been linked to potentially fatal abnormal heart rhythms in some patients with liver disease or who also take the antifungal drug ketoconazole or the antibiotic erythromycin. In animal and human metabolic studies, terfenadine was shown to undergo high first-pass effect, which results in readily measurable plasma concentrations of the major metabolite 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-&agr;,&agr;-dimethylphenylacetic acid, also known as terfenadine carboxylic acid metabolite. The terfenadine carboxylic acid metabolite also possesses anti-histaminic activity in animal models and may lack the cardiac side effects seen with terfenadine.
Piperidine derivatives related to the terfenadine carboxylic acid metabolite are disclosed in the following U.S. patents:
U.S. Pat. No. 4,254,129 to Carr, et. al.
U.S. Pat. No. 4,254,130 to Carr, et. al.
U.S. Pat. No. 4,285,957 to Carr, et. al.
U.S. Pat. No. 4,285,958 to Carr, et. al.
In these patents, 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-&agr;-&agr;-dimethylbenzeneacetic acid and related compounds are prepared by alkylation of a substituted piperidine derivative of the formula:
with an &ohgr;-haloalkyl substituted phenyl ketone of the formula:
wherein the substituents halo, R
1
, R
2
, n, z, and R
6
are described in column 6 of U.S. Pat. No. 4,254,130.
It is further described that the halo alkyl substituted phenyl ketone wherein Z is hydrogen are prepared by reacting an appropriate straight or branched lower alkyl C
1-6
ester of &agr;-&agr;-dimethylphenylacetic acid with the compound of the following formula:
under the general conditions of a Friedel-Crafts acylation, wherein halo and m are described in column 11 of U.S. Pat. No. 4,254,129. The reaction is carried out in carbon disulfide as the preferred solvent.
Applicant has discovered that the preparation of ethyl 4-(4-chloro-1-oxobutyl)-&agr;,&agr;-dimethylphenylacetate by reaction of 4-chlorobutyryl chloride, aluminum chloride, and ethyl &agr;,&agr;-dimethylphenylacetate in carbon disulfide, as described in Example 1 of U.S. Pat. Nos. 4,254,130 and 4,285,958 provides an inseparable mixture of monosubstituted aromatic regioisomers of the formula:
wherein the chlorobutyryl substituent is attached at either of the three aromatic carbons which are meta or para to the dimethylacetate substituent. These regioisomers are not separable by standard techniques of thin layer chromatography, or column chromatography, and low field proton nuclear magnetic resonance spectroscopy is inconclusive in identifying the product of this reaction as a mixture. When the mixture of monosubstituted aromatic regioisomers of the preceding formula is reacted with a piperidine of the formula:
a second mixture of aromatic regioisomers is obtained of the formula:
wherein the monosubstituted meta, para mixture of regioisomers is obtained.
It is known in the art that a monoalkyl substituent on a benzene ring is ortho, para directing in electrophilic aromatic substitution reactions such as a Friedel-Crafts reaction. Thus, it would be expected that the Friedel-rafts reaction of &agr;-chlorobutyryl chloride with ethyl &agr;,&agr;-dimethylphenylacetate would yield predominantly the para substituted product of the formula:
because of the electron donating, para-directing character of the dimethylalkyl substituent combined with the steric hindrance associated with reaction of the ortho positions. In practice, the inductive electronic withdrawing effect of the carboxylic ester of ethyl &agr;,&agr;-dimethylphenylacetate counteracts the expected alkyl electron donating effect, resulting in no significant directing effect for the aromatic substitution reaction. For the described reaction, a statistical mixture of meta to para regioisomers results, with the two meta positions predominating.
The above second mixture of regioisomers can be converted to a third mixture of regioisomers of formula:
Although the second mixture of regioisomers and the third mixture of regioisomers can be analyzed by HPLC experiments, a practical separation to obtain gram quantities of substantially pure regioisomers has not been achieved. Each mixture (including the first), would be expected to contain 33% of the para isomer and 67% of the meta isomer. Since these components are inseparable, it has not been possible to obtain either of the regioisomers in each mixture in substantially pure form.
SUMMARY OF THE INVENTION
The present invention relates to substantially pure piperidine derivative compounds of the formulae:
wherein
R
1
is hydrogen or hydroxy;
R
2
is hydrogen;
or R
1
and R
2
taken together form a second bond between the carbon atoms bearing R
1
and R
2
;
R
3
is —COOH or —COOR
4
;
R
4
is an alkyl with 1 to 6 carbon atoms;
A, B, and D are the substituents of their rings, each of which may be different or the same, and are selected from the group consisting of hydrogen, halogens, alkyl, hydroxy, alkoxy, or other substituents
or a salt thereof. These compounds are useful in pharmaceutical compositions, particularly as antihistamines, antiallergy agents, and bronchodilators.
The piperidine derivative compound is prepared by a process which is initiated by providing a substantially pure regioisomer of the following formula:
The substantially pure regioisomer is converted to the piperidine derivative having a keto group with a piperidine compound of the formula:
A number of synthetic pathways for preparing the substantially pure regioisomer and for reacting it with the piperidine compound having a keto group are disclosed. The piperidine derivative having a keto group can be converted to the above piperidine derivative having a hydroxyl group by reduction.
Although a wide variety of piperidine derivatives can be produced by the process of the present invention, it is particularly useful in forming a hydroxylated piperidine derivative of the formula:
Alternatively, the process of the present invention can be used to produce a piperidine derivative with a keto group of the following formula:
REFERENCES:
patent: 3687956 (1972-08-01), Zivkovic
patent: 3806526 (1974-04-01), Carr et al.
patent: 3829433 (1974-08-01), Carr et al.
patent: 3839431 (1974-10-01), Sheehan et al.
patent: 3862173 (1975-01-01), Carr et al.
patent: 3878217 (1975-04-01), Carr et al.
patent: 3898271 (1975-08-01), Sheehan et al.
patent: 3922276 (1975-11-01), Duncan et al.
patent: 3931197 (1976-01-01), Carr et al.
patent: 3941795 (1976-03-01), Carr et al.
patent: 3946022 (1976-03-01), Carr et al.
patent: 3956296 (1976-05-01), Duncan et
AMR Technology , Inc.
Chang Celia
Heslin Rothenberg Farley & & Mesiti P.C.
LandOfFree
Piperidine derivatives and process for their production does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidine derivatives and process for their production, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine derivatives and process for their production will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3228595